/ELTX
ELTX Stock - Elicio Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$7.94-0.63%
$0.05 (-0.63%) • Dec 19
24
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.26
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.37
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-81.1%upside
Target: $1.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ELTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.86 – $8.02
TARGET (TP)$1.50
STOP LOSS$7.30
RISK/REWARD1:-10.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.08
52W High$12.62
52W Low$4.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $28.31M | $2.88M |
| Gross Profit | $-1,178,000 | $-1,170,000 | $-1,057,000 | $27.08M | $1.06M |
| Gross Margin | N/A | N/A | N/A | 95.6% | 36.9% |
| Operating Income | $-44,986,000 | $-35,745,000 | $-23,733,000 | $-39,307,000 | $-55,273,000 |
| Net Income | $-51,898,000 | $-35,195,000 | $-28,208,000 | $-26,400,698 | $-80,107,000 |
| Net Margin | N/A | N/A | N/A | -93.2% | -2781.5% |
| EPS | $-4.25 | $-6.96 | $-9.10 | $-19.32 | $-1.93 |
Company Overview
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ELTXBeat Rate
54%
Last 13 quarters
Avg Surprise
-4.1%
EPS vs Estimate
Beats / Misses
7/6
Last 12 quarters
Latest EPS
$-0.60
Q4 2025
EPS Surprise History
Q1 24
-124.4%
$-1.75vs$-0.78
Q2 24
-5.5%
$-1.15vs$-1.09
Q3 24
+33.3%
$-0.64vs$-0.96
Q4 24
-71.6%
$-1.39vs$-0.81
Q1 25
-8.5%
$-1.02vs$-0.94
Q2 25
-29.9%
$-0.87vs$-0.67
Q3 25
+4.3%
$-0.66vs$-0.69
Q4 25
+3.2%
$-0.60vs$-0.62
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.47 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.62 | $-0.60 | +3.2% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.69 | $-0.66 | +4.3% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.67 | $-0.87 | -29.9% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.94 | $-1.02 | -8.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.81 | $-1.39 | -71.6% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.96 | $-0.64 | +33.3% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-1.09 | $-1.15 | -5.5% | ✗ MISS |
Q1 2024 | Feb 13, 2024 | $-0.78 | $-1.75 | -124.4% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.80 | $-1.27 | -58.7% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-5.70 | $-2.61 | +54.2% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.54 | $-0.15 | +72.2% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-2.15 | — | — |
Q3 2022 | Sep 30, 2022 | $-3.20 | $-2.27 | +29.2% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-4.63 | $-2.37 | +48.9% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-4.75 | — | — |
Q4 2021 | Dec 31, 2021 | — | $4.97 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-5.26 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-5.75 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.47 | — | — |
Latest News
Elicio Therapeutics Announces That Analysis Of Subset Of Patients In Ongoing Phase 2 AMPLIFY-7P Trial Shows That Majority Of Evaluated Patients Treated With ELI-002 7P Induced Antigen Spreading Targeting Non-mKRAS Neoantigens That Are Not Present In ELI-002 7P Targeted Immunotherapy
📈 PositiveBenzinga•Dec 11, 2025, 01:04 PM
Elicio Therapeutics Q3 EPS $(0.60) Misses $(0.55) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:32 PM
Elicio Announces Additional Immunogenicity Data From Ongoing Phase 2 AMPLIFY-7P Trial Evaluating ELI-002 7P In Patients With mKRAS PDAC And New Preclinical Data On Immunotherapy Candidate ELI-004, For Treatment Of Solid Tumors
📈 PositiveBenzinga•Nov 7, 2025, 02:10 PM
Elicio Therapeutics Announced That Preliminary Analysis Of Patients In The Ongoing Phase 2 AMPLIFY-7P Trial Indicated That Specific Human Leukocyte Antigen Types; ELI-002 7P Shows Broad T-Cell Response Against mKRAS-Mutated Cancers Across Diverse Patient HLA Types
📈 PositiveBenzinga•Oct 27, 2025, 12:22 PM
Elicio Therapeutics Announces Planned Initiation Of Investigator-Initiated Phase 1 Trial Of ELI-002 7P In Combination With Chemotherapy And Anti-PD1 Checkpoint Inhibitor In Borderline And Resectable PDAC
📈 PositiveBenzinga•Sep 29, 2025, 12:19 PM
Elicio's ELI-002 Triggers mKRAS-Specific T Cell Responses In 99% Of Phase 2 AMPLIFY-7P Trial Patients
📈 PositiveBenzinga•Sep 17, 2025, 12:08 PM
Frequently Asked Questions about ELTX
What is ELTX's current stock price?
Elicio Therapeutics, Inc. (ELTX) is currently trading at $7.94 per share. The stock has moved -0.63% today.
What is the analyst price target for ELTX?
The average analyst price target for ELTX is $1.50, based on 1 analyst.
What sector is Elicio Therapeutics, Inc. in?
Elicio Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ELTX's market cap?
Elicio Therapeutics, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does ELTX pay dividends?
No, Elicio Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTU
Actuate Therapeutics Inc
$6.98
Mkt Cap: $0.2B
APLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.12
Mkt Cap: $0.1B
CRDF
Cardiff Oncology, Inc.
$2.57
Mkt Cap: $0.2B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
RANI
Rani Therapeutics Holdings, Inc.
$1.51
Mkt Cap: $0.1B
SAVA
Cassava Sciences, Inc.
$2.17
Mkt Cap: $0.1B
Explore stocks similar to ELTX for comparison